Garheng Kong is founder and managing partner of HealthQuest Capital. He has over two decades of experience in the healthcare field as an investor, physician, scientist, and engineer.
Dr. Kong’s investments and board directorships have resulted in the IPOs of Cempra (CEMP), Alimera (ALIM), Applied Genetic Technology Corp. (AGTC), Proteon (PRTO), Histogenics (HSGX) and TransEnterix (TRXC). He has also had board roles in many M&A transactions that include Calibra Medical (J&J), Cellective (AstraZeneca), Serenex (Pfizer), Athenix (Bayer), NovaMin (GSK), Aldagen (Cytomedix), Salveo Specialty Pharmacy (Catamaran) and SARCode (Shire). Dr. Kong has been asked to Chair the board of seven companies as well.
Dr. Kong is a member of the board of directors of Laboratory Corporation of America (LabCorp, NYSE:LH) and Duke University Medical Center as well as Alimera Sciences (ALIM), Castle Biosciences, Cempra (CEMP), First Aid Shot Therapy, Histogenics (HSGX), Strongbridge (SBBP), Trice Medical and VirMedica. Dr. Kong’s interests and industry footprint are broad as he also serves on the board of SEBIO, Corporate Chaplains of America, Cure Network Ventures, and advises IDEO Palo Alto and numerous industry groups. He has also served on the Duke Medical Center Institutional Review Board (IRB) and as faculty at the Duke Fuqua School of Business as a senior scholar.
Dr. Kong received two undergraduate degrees, in chemical engineering and biological sciences, from Stanford University, which he attended on an athletic scholarship. He then earned his MD, PhD and MBA from Duke University, graduating at the top of his class in each instance. His early career included stints at GlaxoSmithKline, McKinsey & Co. and medical device startup TherOx. Dr. Kong has been founder and CEO of two successful biopharma companies (Cellective and Viamet). Prior to HealthQuest, he was a general partner at Intersouth Partners and a general partner at Sofinnova Ventures.
Paul Meister is President of MacAndrews & Forbes Incorporated. He is also co-founder of Liberty Lane Partners, LLC, a private investment company with investments in healthcare, technology, and distribution-related industries and Perspecta Trust, a trust company that provides trust and investment services. Mr. Meister previously served as Chairman and CEO of inVentiv Health, a leading provider of commercial, consulting and clinical research services to the pharmaceutical and biotech industries.
Prior to that, he served as Chairman of the Board of Thermo Fisher Scientific Inc. and Vice Chairman of Fisher Scientific International, Inc. prior to Fisher’s merger with Thermo. During his tenure as an executive officer of Fisher Scientific, from 1991 to 2006, the company’s revenue and operating income grew at a compound annual growth rate of 15% and 23% respectively as operations grew from two countries to 27 and sales expanded into 140 countries worldwide.
Earlier in his career, Mr. Meister served in a number of executive leadership positions at Wheelabrator Technologies Inc., The Henley Group Inc., and AlliedSignal Inc. (now Honeywell International, Inc.). He began his career with Ford Motor Company.
Mr. Meister holds a Bachelor of Arts degree from the University of Michigan and an MBA from Northwestern University. He is a director of LKQ Corporation, Scientific Games Corporation, Quanterix Corporation; co-chair of the University of Michigan’s Life Sciences Institute External Advisory Board and serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University.
Greg Bullington is co-founder and CEO of Magnolia Medical Technologies. Mr. Bullington has led all commercial aspects of company development since inception including clinical trial design and execution, peer-reviewed publication, product development, manufacturing, commercial launch and overall intellectual property strategy.
Mr. Bullington has extensive experience in the healthcare industry having led product commercialization and strategy engagements for a wide variety of companies in the biotech (novel immunotherapy), healthcare insurance, wellness and enterprise software sectors.
Mr. Bullington began his career in professional services with the Audit & Assurance practice of Deloitte & Touche LLP. He continued his professional development as a management consultant with Lake Partners, a Seattle-based strategy firm. In 2006, Mr. Bullington founded Forum Ventures, a technology commercialization consultancy focused on accelerating the growth of early and mid-stage technology companies.
Over the past 15 years, Mr. Bullington has led engagements and worked with senior executive teams at over 50 companies ranging from Fortune 100 corporations to venture-backed and early stage startups as a consultant, advisor, and investor. Additionally, Mr. Bullington has significant intellectual property expertise and is an inventor on over 50 issued and pending US as well as international patents.
Dr. Patton is a board-certified pathologist with more than 40 years of active practice experience. Recognizing the patient safety and financial implications of false positive blood cultures, he has long been interested in exploring opportunities to reduce contamination rates.
In 2006, Dr. Patton designed a clinical trial to test the effectiveness of Initial Specimen Diversion Technique (ISDT), an innovation that he conceived earlier in his career. The results of the trial were significantly positive and published in the peer-reviewed Journal of Clinical Microbiology.
Dr. Patton’s areas of expertise are clinical microbiology, gastrointestinal pathology, and cytopathology. He was the Chief of Pathology and Medical Director of Clinical Laboratories at Northwest Hospital, Seattle, Washington for four decades. He has served as a Laboratory Inspector, Washington State Commissioner, NW Regional Commissioner, and Accreditation and Complaints Committee Member for the College of American Pathologists Laboratory Accreditation Program.
Josh is a Venture Partner at Split Rock Partners, and also serves as a Venture Partner at SightLine Partners. He has been with Split Rock since 2004 and with SightLine since 2014. Mr. Baltzell has over 20 years of experience in the healthcare industry.
Prior to his tenure in the venture capital industry, Josh held roles as an investment banker at Piper Jaffray Companies from 2000 to 2002, where he focused primarily on mergers and acquisitions in the medical device sector as well as various marketing and business development positions with SCIMED and Boston Scientific. Josh currently serves on the boards of Colorescience, EBR Systems, Inc., Entellus Medical (NASDAQ: ENTL), Histogenics Corporation (NASDAQ: HSGX) and Nanocyte Medical. Josh is also a co-inventor of the DentaDish.
Josh’s previous investments and board affiliations have resulted in several M&A transactions including Ardian (Medtronic), Dfine (Merit Medical), RF Surgical (Medtronic), Skinmedica (Allergan) and Tarsus (Integra Lifesciences).
Josh holds a B.A. in Economics from St. Olaf College and an M.B.A. from the University of Minnesota’s Carlson School of Management.
Paul Enever is a managing director at Canepa Healthcare. Before joining Canepa, Paul was a partner at McKinsey and Company. In his 12 years at McKinsey, he advised leading organizations across the bio-pharma, med-tech, hospital, and healthcare services industries primarily in the U.S. and Europe as well as private equity firms specializing in healthcare. Paul’s work focused on growth strategy, sales and marketing, and licensing and acquisition. Previously, Paul worked within the R&D organization at Sandoz Pharmaceuticals and MIT’s Biotechnology Process Engineering Center.
He sits on the Boards of Directors of Cardiva Medical, Dune Medical Devices, and Magnolia Medical Technologies.
Paul has a B.S. in chemical engineering from Rensselaer Polytechnic Institute and a Ph.D. in chemical engineering from the University of Minnesota where he studied wound healing and tissue engineering. For his work, Paul was the recipient of both a National Science Foundation Graduate Fellowship and the Whitaker Foundation Graduate Fellowship in Biomedical Engineering.